ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
Open Access
- 18 September 2021
- journal article
- Published by Impact Journals, LLC in Aging
- Vol. 13 (18) , 22286-22297
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2020
- Next-generation therapies for adrenocortical carcinomaBest Practice & Research Clinical Endocrinology & Metabolism, 2020
- Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal CancerAdvanced Science, 2019
- Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivoInternational Journal of Cancer, 2018
- Comprehensive Pan-Genomic Characterization of Adrenocortical CarcinomaCancer Cell, 2016
- Penetrance of pathogenic mutations in haploinsufficient genes for intellectual disability and related disordersEuropean Journal of Medical Genetics, 2015
- Genetics and epigenetics of adrenocortical tumorsMolecular and Cellular Endocrinology, 2014
- The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validationEuropean Journal of Cancer, 2010
- Outcome of adrenocortical tumors in childrenJournal of Pediatric Surgery, 2008
- Candidate Diagnostic Markers and Tumor Suppressor Genes for Adrenocortical Carcinoma by Expression Profile of Genes on Chromosome 11q13World Journal of Surgery, 2008